• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Atsena Therapeutics Announces Presentations at ARVO

    FIRSTWORD PHARMA

    Genezen, Atsena Therapeutics Partner For Commercial Manufacturing

    PR NEWSWIRE

    Atsena Wraps Dosing In Phase I/II/III LIGHTHOUSE Trial

    GLOBENEWSWIRE

    Atsena Completes Adult Dosing In Atsn-201 Trial For X-Linked

    GLOBENEWSWIRE

    Atsena gene therapy hits safety goals, closes retinal splits

    FIERCE BIOTECH

    Atsena Therapeutics to Present at May Scientific Conferences

    GLOBENEWSWIRE

    Atsena Gets RMAT Tag for Gene Therapy in Retinoschisis

    GLOBENEWSWIRE

    Atsena Therapeutics Raises $150M in Series C Financing

    GLOBENEWSWIRE

    Atsena to Present ATSN-201 Safety Data at Macula Society Meeting

    GLOBENEWSWIRE

    Nippon Shinyaku & Atsena Partner on ATSN-101 in U.S. & Japan

    GLOBENEWSWIRE

    Atsena To Present ATSN-201 Data At AAO 2024 Annual Meeting

    GLOBENEWSWIRE

    Atsena Therapeutics to Present at Chardan’s Genetic Medicines Conference

    GLOBENEWSWIRE

    Atsena Therapeutics Announces 12-Month Phase I/II Trial Data

    GLOBENEWSWIRE

    Atsena: Positive ATSN-201 Gene Therapy Data In XLRS Trial Phase I/II

    GLOBENEWSWIRE

    Atsena Announces Initiation of Dosing in Phase I/II Trial Evaluating ATSN-201

    GLOBENEWSWIRE

    Atsena Receives Rare Pediatric Disease Designation from FDA for ATSN-101

    GLOBENEWSWIRE

    Atsena Announces Positive 12-month Safety Data from Phase I/II of ATSN-101

    GLOBENEWSWIRE

    Atsena Announces First Patient Dosed in Ph I/II Clinical Trial of ATSN-201

    GLOBENEWSWIRE

    Atsena Announces Six-Month Data from Phase I/II Clinical Trial of ATSN-101

    GLOBENEWSWIRE

    Atsena to Present Positive Data from the Phase I/II Clinical Trial of ATSN-101

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.